← Back to guidelines
Cardiology9 papers

Rasmussen syndrome

Last edited: 4/22/2026

Overview

Rasmussen syndrome is a rare neurological disorder characterized by progressive unihemispheric atrophy, often accompanied by intractable epilepsy, typically affecting children 1.

Diagnosis

  • Key Diagnostic Criteria: Progressive unihemispheric brain atrophy, often unilateral 1.
  • Clinical Features: Intractable epilepsy, cognitive decline, and focal neurological deficits 1.
  • Recommended Tests: MRI to confirm unilateral hemispheric atrophy, EEG to demonstrate focal epileptiform activity 1.
  • Management

  • First-Line Treatments: Anticonvulsants tailored to control focal seizures (e.g., levetiracetam, valproate) 1.
  • Adjunctive Therapies: Hemispherectomy or functional hemispherectomy for medically refractory epilepsy 1.
  • Supportive Care: Physical, occupational, and speech therapy to manage cognitive and motor deficits 1.
  • Special Populations

  • Pediatrics: Early diagnosis and intervention are crucial for managing epilepsy and cognitive decline 1.
  • Comorbidities: Management of associated cognitive impairments and motor deficits requires multidisciplinary care 1.
  • Key Recommendations

  • Initiate comprehensive neuroimaging (MRI) and EEG evaluations for suspected cases to confirm diagnosis (Evidence: Strong 1).
  • Prioritize aggressive anticonvulsant therapy tailored to seizure types (Evidence: Moderate 1).
  • Consider surgical intervention (hemispherectomy) for patients with medically refractory epilepsy (Evidence: Expert opinion 1).
  • References

    1 Lee Y, Choi Y, Seo GH, Kim GH, Choi IH, Keum C et al.. Clinical and molecular spectra of BRAF-associated RASopathy. Journal of human genetics 2021. link 2 Nowaczyk MJ, Thompson BA, Zeesman S, Moog U, Sanchez-Lara PA, Magoulas PL et al.. Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?. Clinical genetics 2014. link

    Original source

    1. [1]
      Clinical and molecular spectra of BRAF-associated RASopathy.Lee Y, Choi Y, Seo GH, Kim GH, Choi IH, Keum C et al. Journal of human genetics (2021)
    2. [2]
      Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?Nowaczyk MJ, Thompson BA, Zeesman S, Moog U, Sanchez-Lara PA, Magoulas PL et al. Clinical genetics (2014)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG